Company Profile
NKGen Biotech, Inc. Stock Price, News & Analysis
- Ticker:
- NKGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.01 USD (-49.50%)
Close
Last updated: August 4, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for NKGN.
Company overview
Business overview
NKGen Biotech is a cell-therapy company focused on natural killer cell approaches for cancer and immune-related disease. Its story is centered on using engineered immune cells to attack tumors in a different way from CAR-T.
Geographic Base and Sector Classification
NKGen Biotech is headquartered in the United States and listed on NASDAQ. It sits in cell therapy and oncology biotechnology.
Business Model Characteristics
The company depends on translational validation, manufacturing feasibility, and capital support while developing a narrow pipeline. Investors watch early data, safety, and platform differentiation.
Position Within the Biotechnology Landscape
NKGen occupies a specialized NK-cell niche within biotech. It is catalyst-sensitive because the market still wants proof that the platform can matter clinically.
Future catalysts
NKGen’s catalysts are NK-cell therapy programs and any update that shows the platform can still advance clinically. The company remains early and highly data-dependent.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NKGen Biotech, Inc. (NKGN)?
NKGen Biotech, Inc. (NKGN) most recently closed at 0.01 USD, a -49.50% move versus the previous session.
What does NKGen Biotech, Inc. do?
NKGen Biotech is a cell-therapy company focused on natural killer cell approaches for cancer and immune-related disease. Its story is centered on using engineered immune cells to attack tumors in a different way from CAR-T.
On which exchange is NKGN stock listed?
NKGen Biotech, Inc. (NKGN) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Its story is centered on using engineered immune cells to attack tumors in a different way from CAR-T.
Which conditions is NKGen Biotech, Inc. targeting with CAR-T?
NKGen Biotech, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does NKGen Biotech, Inc. describe recent progress with CAR-T?
NKGen’s catalysts are NK-cell therapy programs and any update that shows the platform can still advance clinically. The company remains early and highly data-dependent.
What is NKGen?
NKGen Biotech is a cell-therapy company focused on natural killer cell approaches for cancer and immune-related disease.
What should investors watch for with NKGen?
NKGen’s catalysts are NK-cell therapy programs and any update that shows the platform can still advance clinically.